DRUG · Mapped RxNorm record
Liraglutide
Normalized identity: liraglutideView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
NCT02055014
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DEVICE · Unmapped registry intervention
Duodenal-jejunal bypass liner - Endobarrier device
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedRandomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Obesityverified · MONDO: obesity disorder
Diabesityunresolved
Interventions
LiraglutideDRUG · verified · RxNorm: liraglutide
Sponsors & collaborators
Sandwell & West Birmingham Hospitals NHS Trustlead sponsor
Association of British Clinical Diabetologistscollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02055014 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.